ANG Lifesciences Stock Screener | Share Price & Fundamental Analysis

ANG Pharmaceuticals
Screen ANG Lifesciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹28.10
▲ 0.04 (0.14%)
2026-01-09 00:00:00
Market Cap ₹38.48 Cr.
P/B Ratio 0.64
EPS (TTM) ₹-9.42
Dividend Yield -
Debt to Equity 1.11
52W High ₹43.91
52W Low ₹21.64
Operating Margin -4.00%
Profit Margin -11.11%
Revenue (TTM) ₹18.00
EBITDA -
Net Income ₹-2.00
Total Assets ₹230.00
Total Equity ₹64.00

ANG Lifesciences Share Price History - Stock Screener Chart

Screen ANG historical share price movements with interactive charts. Analyze price trends and patterns.

ANG Lifesciences Company Profile - Fundamental Screener

Screen ANG Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ANG shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE236W01016

ANG Lifesciences Balance Sheet Screener - Fundamental Analysis

Fair Value Analysis
Screen ANG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022
Assets
Total Assets 230 242 278 291
Current Assets 161 173 183 193
Fixed Assets 57 58 88 93
Liabilities
Total Liabilities 230 242 278 291
Current Liabilities 22 22 29 41
Non-Current Liabilities 0 0 0 0
Shareholders' Equity
Total Equity 64 76 86 84
Share Capital 13 13 13 10
Reserves & Surplus 46 59 69 69
Screen ANG income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept 2022-Dec
Revenue 18 25 26 38 20 33 25 49 57 34 19 96 74 60 47
Expenses 18 24 26 36 20 31 27 50 50 32 21 83 62 50 44
EBITDA 0 1 0 2 0 3 -2 -1 7 2 -2 13 12 10 3
Operating Profit % -4.00% 3.00% 0.00% 4.00% -9.00% 7.00% -9.00% -26.00% 12.00% 5.00% -10.00% 13.00% 16.00% 16.00% 6.00%
Depreciation 1 2 2 2 2 2 2 3 2 2 2 3 2 2 2
Interest 2 2 2 4 2 2 2 2 2 2 3 4 3 3 4
Profit Before Tax -4 -3 -3 -4 -4 -1 -6 -6 2 -3 -6 7 7 4 -3
Tax -2 -1 0 0 -1 1 -1 -1 1 0 0 2 3 2 -1
Net Profit -2 -2 -3 -4 -3 -2 -5 -5 2 -2 -6 5 4 3 -2
EPS -1.56 -1.52 -2.24 -2.75 -2.35 -1.53 -3.98 -3.63 1.41 -1.74 -4.52 5.16 3.99 2.20 -1.36

ANG Lifesciences Cash Flow Screener - Liquidity Fundamentals

Screen ANG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March
Operating Activities 0 -10 26 25
Investing Activities -2 20 -9 -44
Financing Activities 2 -10 -17 20
Net Cash Flow 0 0 0 0
Screen ANG shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar
Promoter Holding 70.60% 70.60% 70.60% 70.60% 70.60% 70.60% 70.60% 70.60%
FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 26.11% 26.11% 26.18% 25.62% 25.48% 25.45% 25.92% 26.13%
Other Holding 3.29% 3.29% 3.21% 3.78% 3.92% 3.95% 3.48% 3.27%
Shareholder Count 6,508 6,400 6,273 6,868 6,631 6,468 6,517 7,163

ANG Lifesciences Dividend Screener - Share Yield Analysis

Screen ANG dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Period Dividend Per Share Dividend Yield
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹1.00 1.33%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%
2016-March ₹0.00 0.00%

ANG Lifesciences Index Membership - Market Screener Classification

Screen ANG by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
ANG Lifesciences is not part of any tracked indices.
Only major market indices are tracked in our system.

ANG Lifesciences Market Events Screener - Corporate Actions

Screen ANG market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
Announcement Date Record Date Event Type Information Price Impact
Annual General Meeting NA -1.68%
Bonus 1:1 -
Annual General Meeting NA -8.62%
2025-11-14 2025-11-14 Quarterly Result Announcement NA -2.04%
2025-08-14 2025-08-14 Quarterly Result Announcement NA -3.93%
2025-05-30 2025-05-30 Quarterly Result Announcement NA -5.27%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -5.83%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -4.04%
2022-07-13 2022-07-14 Bonus 1:4 36.04%
2021-11-02 2021-11-04 Dividend ₹ 1.00 /share 47.69%
2016-05-18 2016-05-18 Change Of Name NA -

ANG Lifesciences Competitors Screener - Peer Comparison

Screen ANG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 416,764 40.16 54,729 9.71% 10,980 46.18
Divis Laboratories 172,462 69.16 9,712 18.67% 2,191 53.62
Torrent Pharmaceuticals 129,770 60.40 11,539 6.99% 1,911 62.04
Cipla 120,864 22.30 28,410 7.12% 5,291 44.91
Dr Reddys Laboratories 105,645 18.66 33,741 16.73% 5,725 60.09
Lupin 96,238 22.21 22,910 13.74% 3,306 60.88
Zydus Life Science 92,352 18.57 23,511 18.55% 4,615 47.29
Mankind Pharma 90,530 51.90 12,744 20.90% 2,007 53.62
Aurobindo Pharma 70,358 20.66 32,346 9.43% 3,484 57.50
Alkem Laboratories 66,550 27.75 13,458 3.70% 2,216 47.48

ANG Lifesciences Company Announcements - News Screener

Screen ANG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-01-08 Closure of Trading Window View
2025-11-14 Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2025 View
2025-11-14 Board Meeting Outcome for Board Meeting Outcome For To Consider And Approve The Financial Results For The Quarter And Half Year Ended 30-09-2025 View
2025-11-06 Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On 30Th September 2025. View
2025-10-15 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 View
2025-10-01 Shareholder Meeting / Postal Ballot-Scrutinizers Report View
2025-09-30 Appoitment Of Secretarial Auditor View
2025-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM View
2025-09-24 Closure of Trading Window View
2025-09-12 Clarification On Price Movement View
2025-09-12 Clarification Sought from ANG Lifesciences India Ltd -
2025-09-12 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2025-09-06 Reg. 34 (1) Annual Report. View
2025-09-06 Notice Of 19Th AGM Of The Company Scheduled To Be Held On 30Th September 2025 View
2025-09-06 Intimation Of Book Closure View
2025-09-06 19Th Annual General Meeting (AGM) Of The Shareholders Of The Company Will Be Held On Tuesday The 30Th September 2025 At 11:30 AM Through Video Conference (VC) / Other Audio Visual Means (OAVM) View
2025-09-06 Board Meeting Outcome for Board Meeting Outcome For Intimation Of AGM View
2025-08-14 Standalone & Consolidated Unaudited Financial Results For The Quarter Ended 30.06.2025. View
2025-08-14 Board Meeting Outcome for Board Meeting Outcome For Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended June 30 2025 View
2025-08-06 Board Meeting Intimation for Conducting Board Meeting To Consider And Approve Unaudited Standalone & Consolidated Financial Results For The First Quarter Ended 30Th June 2025. View